Angiopoietin-2 level as a tool for cardiovascular risk stratification in hypertensive type 2 diabetic subjects

References

• International Diabetes Federation. IDF diabetes atlas [Internet]. 7th. Brussels, Belgium: International Diabetes Federation; 2015. Available from: http://www.diabetesatlas.org
   Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 2015;131:e29–322.
   Google Scholar
• Al-Rubeaan K, Youssef AM, Ibrahim HM, et al. All-cause mortality and its risk factors among type 1 and type 2 diabetes mellitus in a country facing diabetes epidemic. Diabetes Res Clin Pract. 2016;118:130–139.
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Stehouwer CDA. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci Lond Engl. 1979 2005;109:143–159.
   Google Scholar
• Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(Suppl 2):S14–S21.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Venneri MA, Fiore D. Angiopoietin-1 and angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes. J Endocrinol Invest. 2016;39:1235–1246.
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674.
   PubMed Web of Science ®Google Scholar
• Taube A, Schlich R, Sell H, et al. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2012;302:H2148–H2165.
   PubMed Web of Science ®Google Scholar
• Rasul S, Reiter MH, Ilhan A, et al. Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2011;10:55.
   PubMed Web of Science ®Google Scholar
• Lim HS, Lip GYH, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis. 2005;180:113–118.
   PubMed Web of Science ®Google Scholar
• Thomas M, Augustin HG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis. 2009;12:125–137.
   PubMed Web of Science ®Google Scholar
• Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013;328:18–26.
   PubMed Web of Science ®Google Scholar
• Li L, ZHeng-Qing Y, Juan-Yu H, et al. Association between interleukin-19 and angiopoietin-2 with vascular complications in type 2 diabetes. J Diabetes Investig. 2016;7:895–900.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF diabetes atlas. 6th. Brussels, Belgium: International Diabetes Federation; 2013. Available from: http://www.idf.org/diabetesatlas
   Google Scholar
• Abuyassin B, Laher I. Diabetes epidemic sweeping the Arab world. World J Diabetes. 2016 25;7:165–174.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–S69.
   PubMed Web of Science ®Google Scholar
• Chobanian A, Bakris G, Black H, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:1001.
   PubMed Web of Science ®Google Scholar
• Anuradha S, Mohan V, Gokulakrishnan K, et al. Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study-74). Metabolism. 2010;59:774–779.
   PubMed Web of Science ®Google Scholar
• Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther. 2006;111:81–98.
   PubMed Web of Science ®Google Scholar
• Bae J-W Hypertension, vascular rarefaction and angiopoietin-1. Korean Circ J. 2011;41(10):575–577.
   PubMed Web of Science ®Google Scholar
• Levy BI, Ambrosio G, Pries AR, et al. Microcirculation in hypertension: a new target for treatment? Circulation. 2001;104:735–774.
   PubMed Web of Science ®Google Scholar
• Lee JS, Song SH, Kim JM, et al. Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor. Cardiovasc Res. 2008;78:572–580.
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60.
   PubMed Web of Science ®Google Scholar
• Korff T, Ernst E, Nobiling R, et al. Angiopoietin-1 mediates inhibition of hypertension-induced release of angiopoietin-2 from endothelial cells. Cardiovasc Res. 2012;94:510–518.
   PubMed Web of Science ®Google Scholar
• Felmeden DC, Spencer CGC, Belgore FM, et al. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens. 2003;16:11–20.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Blann AD. Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new “vascular triad.”. Ann Med. 2004;36:119–125.
   PubMed Web of Science ®Google Scholar
• Nadar SK, Blann A, Beevers DG, et al. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med. 2005;258:336–343.
   PubMed Web of Science ®Google Scholar
• Chong AY, Caine GJ, Freestone B, et al. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol. 2004;43:423–428.
   PubMed Web of Science ®Google Scholar
• Kiefer FN, Neysari S, Humar R, et al. Hypertension and angiogenesis. Curr Pharm Des. 2003;9:1733–1744.
   PubMed Web of Science ®Google Scholar
• Lim HS, Blann AD, Chong AY, et al. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care. 2004;27:2918–2924.
   PubMed Web of Science ®Google Scholar
• Silha JV, Krsek M, Sucharda P, et al. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005 Nov;29(11):1308–1314.
   PubMed Web of Science ®Google Scholar
• Tabata M, Kadomatsu T, Fukuhara S, et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009;10:178–188.
   PubMed Web of Science ®Google Scholar
• Voros G, Maquoi E, Demeulemeester D, et al. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology. 2005;146(10):4545–4554.
   Google Scholar
• Tilton RG, Kawamura T, Chang KC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest. 1997;99:2192–2202.
   PubMed Web of Science ®Google Scholar
• Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J Off Publ Fed Am Soc Exp Biol. 2002;16:1928–1930.
   PubMed Web of Science ®Google Scholar
• Tuo Q-H, Zeng H, Stinnett A, et al. Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol. 2008;294:H2547–H2557.
   PubMed Web of Science ®Google Scholar
• Tuo Q, Xiong G, Zeng H, et al. Angiopoietin-1 protects myocardial endothelial cell function blunted by angiopoietin-2 and high glucose condition. Acta Pharmacol Sin. 2011;32:45–51.
   PubMed Web of Science ®Google Scholar
• Patel JV, Lim HS, Nadar S, et al. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens. 2006;24:117–121.
   PubMed Web of Science ®Google Scholar
• Felmeden DC, Spencer CGC, Chung NAY, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol. 2003;92:400–405.
   PubMed Web of Science ®Google Scholar
• Lee KW, Lip GYH, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation. 2004;110:2355–2360.
   PubMed Web of Science ®Google Scholar
• Patel JV, Lim HS, Varughese GI, et al. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med. 2008;40:215–222.
   PubMed Web of Science ®Google Scholar